Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune PR Newswire LONDON, December 26, 2013 LONDON, December 26, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Tuesday, December 24, 2013, the U.S. equity market advanced. The S&P 500 ended the day at 1,833.32, up 0.29%; the Dow Jones Industrial Average closed at 16,357.55, up 0.39%; and the NASDAQ Composite Index finished at 4,155.42, up 0.16%. The S&P 500 Health Care Sector Index edged 0.08% lower to close the session at 638.05; and the S&P 500 Biotechnology Industry Index finished at 2,784.14, down 0.38%. The S&P 500 Biotechnology Industry Index has gained 1.42% in the previous three trading sessions and 11.23% in the last three months, outperforming the S&P 500, which has gained 1.31% and 8.30% during the respective periods. The major movers in the Health Care Sector included Gilead Sciences Inc. (NASDAQ: GILD), Halozyme Therapeutics Inc. (NASDAQ: HALO), NPS Pharmaceuticals Inc. (NASDAQ: NPSP) and InterMune Inc. (NASDAQ: ITMN). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on GILD, HALO, NPSP, and ITMN now at: http://www.aaaresearchreports.com/register/ Shares in Gilead Sciences Inc. vacillated between $74.21 and $75.03 before closing the day at$74.96, down 0.04%. A total of 4.53 million shares were traded on Tuesday, which is below the daily average volume of 10.26 million. The company's shares have gained 21.43% in the previous three months and 2.08% in the last three trading sessions, outperforming the S&P 500, which has gained 8.30% and 1.31% during the respective periods. Furthermore, Gilead Sciences Inc.'s stock is trading above its 50-day and 200-day moving averages of $70.74 and $59.33, respectively. Download free research on GILD today by registering at: http://www.AAAResearchReports.com/GILD122613.pdf Halozyme Therapeutics Inc.'s stock hit a new 52-week high of $15.71 on Tuesday, finishing the day 1.24% higher at $15.57. The company's stock fluctuated between $15.33 and $15.71 during the trading session. A total of 0.53 million shares were traded, which is below the daily average volume of 1.74 million. The company's shares have gained 59.69% in the previous three months and 9.03% in the last one month, outperforming the S&P 500, which has advanced 8.30% and 1.71% during the respective periods. Moreover, Halozyme Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $13.15 and $8.86, respectively. Sign up and have access to our free report on HALO at: http://www.AAAResearchReports.com/HALO122613.pdf NPS Pharmaceuticals Inc.'s stock edged 0.27% lower on Tuesday, even the US equity market posted gains. The company's shares closed the day at $29.59, after vacillating between $29.15 and $29.86 during the trading session. A total of 0.90 million shares were traded, which is below the daily average volume 2.17 million. Despite Tuesday's decline, the company's shares have surged 22.63% in the previous one month and 10.00% in the last three trading sessions, outperforming the S&P 500, which has gained 1.71% and 1.31% during the respective periods. Further, NPS Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $26.35 and $20.56, respectively. Sign up and read the complimentary report on NPSP at: http://www.AAAResearchReports.com/NPSP122613.pdf InterMune Inc.'s stock closed the day at $14.76, down 0.14% from the previous day's closing price of $14.78. On Tuesday, the company's shares oscillated between $14.53 and $14.90 during the trading session. A total of 0.45 million shares were traded, which is below the daily average volume of 1.06 million. Despite Tuesday's losses, the company's shares have gained 14.51% in the previous one month and 9.41% in the last three trading sessions, outperforming the S&P 500, which has gained 1.71% and 1.31% during the respective periods. Moreover, InterMune Inc.'s stock is trading above its 50-day and 200-day moving averages of $13.58 and $12.21, respectively. The free report on ITMN can be downloaded by signing up now at: http://www.AAAResearchReports.com/ITMN122613.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AAAResearchReports.com/ SOURCE AAA Research Reports Contact: Peter F. Jones - Phone #: +1(646)396-9126
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune
Press spacebar to pause and continue. Press esc to stop.